RxDoctor Payments Data

William Kopfler, MD

Interventional Cardiology · Hammond, LANPI 1912903816

Payments from drug & device makers

$1,352in general payments, 2019–2025

Across 51 payments — averaging $26.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$496
  • Abiomed$148
  • E.r. Squibb & Sons, L.L.C.$142
  • Angiodynamics, Inc.$120
  • Kestra Medical Technology Services, Inc.$73
  • Abbott$71
  • plus $302 from 10 others

What the payments were for

  • Food & beverage$1,352100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,352 in reported general payments places this provider in the 5th percentile of 171 interventional cardiology providers in Louisiana.

See all interventional cardiology providers in Louisiana

Medicare billing

Part B allowed, 2024
$154,226
Medicare patients
1,238
Services billed
3,268

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban561$466,212
EntrestoSacubitril/Valsartan191$174,093
XareltoRivaroxaban166$99,691
Repatha SureclickEvolocumab47$29,737
FarxigaDapagliflozin Propanediol22$14,673
Metoprolol Succinate829$8,369
BrilintaTicagrelor19$7,979
Rosuvastatin Calcium187$2,676
Atorvastatin Calcium312$2,310
Amiodarone Hcl221$2,021
Prasugrel Hcl32$1,966
ClopidogrelClopidogrel Bisulfate189$1,767
Nitroglycerin110$1,747
Amlodipine Besylate352$1,713
Ranolazine ErRanolazine37$1,704

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$55$174,093191 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 5th percentile of 171 interventional cardiology providers in Louisiana.

Other interventional cardiology in Hammond

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →